基石藥業(02616.HK)急性白血病藥獲批內地試驗
基石藥業(02616.HK)公布,在中國獲批開展ivosidenib橋接註冊性I期試驗,用於治療IDH1基因突變的復發或難治性(R/R)急性髓性白血病(AML)患者。
AML是成人中最常見的急性白血病,且疾病進展迅速。目前已經在中國獲批的AML療法中,還沒有針對該患者群體的有效藥物。
公司董事長兼首席執行官江寧軍表示,作為首個也是目前唯一一個在美國獲批的針對攜帶IDH1基因突變的R/RAML的精準治療藥物,同時亦是基石藥業研發管線中唯一已獲得上市許可的產品,ivosidenib在中國獲批推進臨床註冊試驗意義重大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.